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Patients diagnosed with metastatic breast cancer have a dismal 5-year survival rate of only
24%. The RNA-binding protein Hu antigen R (HuR) is upregulated in breast cancer, and
elevated cytoplasmic HuR correlates with high-grade tumors and poor clinical outcome of
breast cancer. HuR promotes tumorigenesis by regulating numerous proto-oncogenes,
growth factors, and cytokines that support major tumor hallmarks including invasion and
metastasis. Here, we report a HuR inhibitor KH-3, which potently suppresses breast cancer
cell growth and invasion. Furthermore, KH-3 inhibits breast cancer experimental lung
metastasis, improves mouse survival, and reduces orthotopic tumor growth. Mechanistically,
we identify FOXQ1 as a direct target of HuR. KH-3 disrupts HuR–FOXQ1 mRNA interaction,
leading to inhibition of breast cancer invasion. Our study suggests that inhibiting HuR is a
promising therapeutic strategy for lethal metastatic breast cancer.
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When diagnosed before metastasis, breast cancer isnearly always curable; however, if metastasis hasalready developed, the 5-year survival rate drops to
24%1. Therefore, the most important improvements in survival
will result from either prevention of metastasis or better control
of already disseminated disease. Identification of new therapeutic
targets and development of potent inhibitors are urgently needed
to combat lethal metastatic breast cancer.
The RNA-binding protein (RBP) Hu antigen R (HuR), also
known as embryonic lethal abnormal vision-like protein 1
(ELAVL1), is a ubiquitously expressed post-transcriptional
regulator2. Post-transcriptional gene regulation is essential for
normal development, but when dysregulated, has many impli-
cations in disease conditions, such as cancer. HuR is broadly
upregulated in virtually all malignancies tested3. Although HuR
predominately localizes in the nucleus, its function of stabiliz-
ing and/or modulating the translation of target mRNA is linked
to the translocation to the cytoplasm4. Cytoplasmic HuR
accumulation is associated with high-grade malignancies with
poor overall survival and disease-free survival, and may be an
independent prognostic factor of poor clinical outcome in
breast cancer5–7. HuR preferentially binds to mRNA bearing
adenine- and uridine-rich elements (ARE), or uridine-rich sequen-
ces, typically located in the 3′-untranslated region (UTR)8,9. ARE is
a specific cis element present in mRNA, which confers to rapid
mRNA decay10. It is generally accepted that cytoplasmic binding
of HuR to these ARE-containing mRNA leads to mRNA stabi-
lization and increased translation by competing with decay fac-
tors in ARE11,12. Over the past two decades, numerous mRNA
has been identified as HuR direct targets. These transcripts, which
encode proto-oncogenes, growth factors and various cytokines,
implicate in cell proliferation, survival, angiogenesis, immune
recognition, invasion and metastasis13. Therefore, HuR is an
emerging target for breast cancer therapy, especially for meta-
static breast cancer.
HuR is reported to interact with the mRNA 3′-UTR of tran-
scription factor Snail14, metallopeptidase MMP-915 and serine
proteinase uPAR16. Snail is responsible for the induction of
epithelial-to-mesenchymal transition (EMT), while MMP-9 and
uPAR are involved in extracellular matrix (ECM) degradation.
Therefore, HuR is thought to promote invasion and metastasis by
increasing expression of the proteins that induce the transition to
a mesenchymal phenotype and degrade ECM. However, the
specific molecular mechanisms underlying HuR effects on inva-
sion and metastasis of breast cancer are not well understood.
We17,18 and others19–22 have sought to identify small molecule
inhibitors that interfere with HuR–mRNA complex. These small
molecules show moderate to high binding affinity to HuR in
different biochemical assays and have been validated as HuR
inhibitors23. However, only a few of them are potently cytotoxic
to cancer cells and therapeutic efficacy of HuR inhibitors was only
examined in bladder cancer xenograft model24 and colorectal
cancer xenograft models25–27.
Here, we report the identification of a HuR small molecule
inhibitor, KH-3. KH-3 potently inhibits breast cancer cell
growth in vitro and in vivo. KH-3 inhibits breast cancer cell
invasion in vitro as well as delays initiation of lung colonies and
improves mouse survival in an experimental metastasis model
in vivo. We also demonstrate that FOXQ1 is one of the
downstream targets that contribute to HuR’s role in breast
cancer invasion. KH-3 suppresses breast cancer cell invasion by
disrupting HuR–FOXQ1 mRNA interaction. Our data provide
a proof of principle that HuR inhibition by KH-3 may be
developed as a promising molecular therapy for inhibiting
progression and metastasis of breast cancer with HuR
overexpression.
Results
High cytoplasmic HuR correlates with poor clinical outcome.
To explore functional roles of HuR in breast cancer progres-
sion, we first initiated a retrospective study of HuR expression
by immunohistochemistry staining of 140 breast cancer patient
samples. Patients’ clinicopathologic variables are summarized
in Supplementary Table 1. As regulation of RNA stability and
translation is mainly related to cytoplasmic localization of HuR,
we focused on the cytoplasmic HuR expression. Cytoplasmic
HuR was negative or low in 63.0% (85/135) and high in 37.0%
(50/135) of 135 technically well-stained specimens. Repre-
sentative immunostaining results are shown in Supplementary
Fig. 1a. We then examined the association of cytoplasmic HuR
expression with other clinicopathologic variables. As shown in
Table 1, high cytoplasmic HuR was significantly correlated with
high tumor grade, low overall survival rate and distant disease-
free survival rate. Furthermore, 63.6% of patients with metas-
tasis had high cytoplasmic HuR while 35.0% of patients without
metastasis had high cytoplasmic HuR, though the difference did
not reach statistical significance because of small number of
patients with metastasis. These data suggest that patients with
high levels of cytoplasmic HuR have higher risk to develop
metastasis. Cytoplasmic HuR expression had no significant
correlation with age, TN stage, AJCC stage, positive lymph
node numbers and relapse.
Similar to univariate analysis in Table 1, when plotting the
percentage of cytoplasmic HuR positively stained cells based on
tumor grade, patients with grade II-III or III breast cancer had a
significantly higher percentage of positively stained cells (Fig. 1a)
compared to patients with grade II breast cancer. Patients with
high cytoplasmic HuR expression had markedly lower overall
survival rate (Supplementary Fig. 1b) and distant disease-free
survival rate (Fig. 1b) compared to those with low cytoplasmic
HuR expression. Taken together, these data suggest that elevated
Table 1 Correlation between cytoplasmic HuR expression
and the clinicopathologic factors (n= 135).
Cytoplasmic HuR,
N (%)
Parameter Low High P*
Age <60 (y) 53 (58.9) 37 (41.1) 0.189
≥60 (y) 32 (71.1) 13 (28.9)
Tumor grade II 67 (72.0) 26 (28.0) 0.002
II-III & III 18 (42.9) 24 (57.1)
T stage T1 33 (66.0) 22 (34.0) 0.590
T2 52 (65.0) 28 (35.0)
N stage 0 46 (63.9) 26 (36.1) 0.860
≥1 39 (61.9) 24 (38.1)
AJCC stage 1+ 2 58 (64.4) 32 (35.6) 0.706
3 27 (60.0) 18 (40.0)
Positive lymph node (n=
126)
<1 39 (59.1) 27 (40.9) 0.715
≥1 38 (63.3) 22 (37.7)
Overall survival (n= 134) Live 72 (68.6) 33 (31.4) 0.010
Dead 12 (41.4) 17 (58.6)
Relapse (n= 134) No 64 (66.0) 33 (34.0) 0.233
Yes 20 (54.1) 17 (45.9)
Metastasis (n= 134) No 80 (65.0) 43 (35.0) 0.100
Yes 4 (36.4) 7 (63.6)
Distant disease-free
survival (n= 134)
Live 70 (69.3) 31 (30.7) 0.007
Dead 14 (42.4) 19 (57.6)
Fisher’s exact test.
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cytoplasmic HuR could serve as a diagnostic biomarker of higher
tumor grade and prognostic marker of poor clinical outcome in
breast cancer, consistent with previous reports6.
HuR inhibition decreases the proliferation and invasion. We
then manipulated the HuR expression level in a highly metastatic
human triple-negative breast cancer (TNBC) cell line, MDA-MB-
231, using shRNA and CRISPR/CAS9 approaches to determine
whether HuR inhibition would affect cell proliferation and
invasion. Constant or inducible shRNA system reduced HuR
protein level ~50% (Supplementary Fig. 2a, b), which resulted in
significantly delayed tumor initiation and smaller tumor volume
in vivo and fewer invaded cells in vitro (Supplementary Fig. 2c–f).
However, cell growth rate and colony formation ability were not
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obviously affected by knocking down HuR level (Supplementary
Fig. 2g, h). In contrast, knocking out (KO) HuR expression using
CRISPR greatly reduced cell proliferation and completely abol-
ished colony formation. Two clones, HuR KO1 and HuR KO2,
with depleted HuR protein level (Fig. 1c), also showed decreased
protein expression levels of three known HuR targets Bcl-228,
XIAP29, and Musashi 2 (Msi2)30 (Fig. 1c, d and Supplementary
Fig. 3). HuR depletion was also confirmed by immuno-
fluorescence staining using the same HuR antibody used for
immunohistochemistry staining (Supplementary Fig. 4). The two
HuR KO clones grew much slower than the parental cells and
cells with control sgRNA (sgControl, Fig. 1e). In the colony
formation assay, HuR KO clones were unable to form any colo-
nies with 200 cells/well seeded, while parental cells and sgControl
formed ~80 colonies per well (Fig. 1f, g). HuR KO clones also
exhibited decreased invasion (Fig. 1h, i). Since HuR KO1 showed
slightly less invasive capacity, we inoculated this clone as well as
the parental cells and sgControl to the mammary fat pad (MFP)
of female athymic mice to examine the tumor formation. In
contrast, HuR KO1 did not form a tumor (Fig. 1j, k). We also
knocked out HuR expression in SUM159 cells to investigate the
generality of the above findings in MDA-MB-231 cells. Similarly,
two SUM159 HuR KO clones had reduced protein expression of
HuR targets (Supplementary Fig. 5a, b) and grew slower than
parental or sgControl cells (Supplementary Fig. 5c). However, in
contrast to MDA-MB-231 HuR KO clones, SUM159 HuR KO
clones could form colonies, but the colony numbers were fewer
than those formed by parental and sgControl cells (Supplemen-
tary Fig. 5d, e). SUM159 HuR KO clones invaded less well
(Supplementary Fig. 5f, g) and had delayed tumor formation as
well as decreased tumor size compared to sgControl cells (Sup-
plementary Fig. 5h, i). These results indicate that HuR promotes
breast cancer cell proliferation, invasion and tumorigenesis, and
are consistent with previous findings in pancreatic and colon
cancer cells31. These findings demonstrate that HuR plays a cri-
tical role in cell proliferation, invasion and tumorigenesis of
breast cancer, making it a promising therapeutic target.
KH-3 is a small molecule inhibitor of HuR. After discovery of
first candidate HuR inhibitors17, we continued our efforts with
the objective to identify inhibitors with increased potency. We
screened 2000 additional compounds composed of 1673 com-
pounds from the National Cancer Institute plus 291 in-house
compounds using the fluorescence polarization (FP) assay
described previously17. The same full-length HuR protein and a
16-mer AREMsi1 RNA oligomer from 3′-UTR of Musashi1 (Msi1,
a known HuR target32) mRNA were used in the screening.
Among the initial hits, besides compound Aza-9, for which we
recently reported nuclear magnetic resonance (NMR) study of its
binding to HuR18, KH-3 was another top hit (Fig. 2a). Compound
KH-3B, which is structurally similar to KH-3 (Fig. 2b), showed no
inhibition at the same concentration; so, it was used as a negative
control of KH-3 in the later studies.
The effect of KH-3 disrupting HuR–AREMsi1 interaction was
validated using FP and AlphaLISA assays. In both assays, KH-3
displayed dose-dependent inhibitory effect with a Ki of 0.83 µM
and 0.72 µM, respectively. KH-3B only exhibited a minor effect at
the highest dose tested (Fig. 2c, d). Surface plasmon resonance
(SPR) was performed to verify the direct binding of KH-3 to HuR
protein. KH-3 bound to full-length HuR protein (Fig. 2e) and
shorter fragment RRM1/2 (Supplementary Fig. 6a) in a dose-
dependent manner; whereas KH-3B showed slight binding at the
highest concentration (Supplementary Fig. 6b, c). We applied
computational docking using the reported crystal structure of
HuR RRM1/2 in complex with RNA (PDB 4ED5) as a starting
point33. Figure 2f represents the top-scoring computational
models for each of KH-3 and KH-3B in complex with HuR
RRM1/2. In both models, the ligand occupies a similar
orientation in the RNA-binding groove, making use of similar
interactions to the uracil base that engages this site in the crystal
structure. In the KH-3 model, the hydroxamic acid moiety forms
two hydrogen bonds to residues Ser-94 and Ile-133 of HuR
RRM1/2 protein; in contrast, KH-3B does not have the
hydroxamic acid group and cannot form an analogous
hydrogen-bonding pattern. This in silico docking result provides
a potential structural rationale for why KH-3 binds to HuR more
tightly than KH-3B.
To confirm that KH-3 binds to endogenous HuR and disrupts
HuR–mRNA interactions in cells, we employed cellular thermal
shift assay (CETSA), RNA pull down and ribonucleoprotein
immunoprecipitation (RNP IP) in MDA-MB-231 cells. KH-3
pre-treatment induced thermal stabilization of HuR compared to
DMSO vehicle control (Fig. 2g, h and Supplementary Fig. 3),
which demonstrates the direct binding of KH-3 to HuR in cells.
In the pull-down experiment, KH-3, but not KH-3B, inhibited
endogenous HuR from binding a biotinylated AREMsi1 RNA
oligomer and being pulled down with streptavidin-coated beads
(Fig. 2i, j and Supplementary Fig. 3), indicating the ability of KH-
3 to block HuR–ARE interactions. In the RNP IP assay, the
significant enrichment of three mRNAs immunoprecipitated by
HuR antibody compared to IgG verified that these three genes are
HuR direct targets in MDA-MB-231 cells. KH-3, but not KH-3B,
significantly disrupted the interaction between HuR and three
target mRNAs (Fig. 2k). This assay was also performed in
SUM159 cells and similar result was obtained (Supplementary
Fig. 6d).
KH-3 blocks HuR function and inhibits breast cancer growth.
After validation of KH-3 as a competitive HuR inhibitor with
various biochemical/biophysical assays, the effects of KH-3 on
human breast cancer cells were examined. KH-3 exhibited potent
cytotoxicity against a panel of TNBC cell lines with IC50 less than
Fig. 1 HuR is a therapeutic target for breast cancer. a Cytoplasmic HuR expression in breast cancer tissues with low or high grade. Patients with high-
grade tumors (II-III or III, n= 42) have higher positively stained cytoplasmic HuR than those with low-grade tumors (II, n= 93) (*P= 0.0176, t-test). b
Kaplan–Meier analysis of the distant disease-free survival of 134 patients comparing high and low cytoplasmic HuR. Patients with high cytoplasmic HuR
have lower distant disease-free survival rate compared to those with low cytoplasmic HuR (**P= 0.0035, log-rank test). c, d Protein expression levels of
HuR and downstream targets in MDA-MB-231 cells, cells with control sgRNA (sgControl) and two HuR KO clones. c Representative WB results from one
experiment. d Quantified relative expression of HuR downstream target Bcl-2, Msi2, and XIAP. Values are mean ± SD from n= 3 independent experiments
(***P < 0.001, two-way ANOVA). e Growth curves of MDA-MB-231 cells, sgControl and two HuR KO clones. Values are mean ± SD from n= 3
independent experiments (***P < 0.001, two-way ANOVA). f, g Colony formation of MDA-MB-231 cells, sgControl and two HuR KO clones. f colony
numbers per well (***P < 0.001, one-way ANOVA, n= 3). g Representative images of colonies. h, i Invasion assay in parental MDA-MB-231 cells,
sgControl and two HuR KO clones. h Representative images of stained invaded cells, scale bars: 200 μm. i The number of invaded cells per image (***P <
0.001, one-way ANOVA, n= 6). j, k Tumor initiation (j) and tumor growth (k) of MDA-MB-231 cells, sgControl and HuR KO1 clone in athymic nude mice.
HuR KO1 is unable to engraft tumor in vivo (n= 10, ***P < 0.001, log-rank test for tumor initiation and two-way ANOVA for tumor growth).
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10 µM except for Hs578T cell line in MTT-based cytotoxicity
assay (Fig. 3a). Compared to the parental cells and sgControl, two
HuR KO clones were less sensitive to KH-3, with the IC50
increased more than two-fold (from ca. 4 μM to 10–11 μM,
Fig. 3b). This result indicates that HuR knockout attenuates the
inhibitory effect of KH-3, and KH-3 cellular activity is HuR
dependent.
Since HuR stabilizes and facilitates the translation of target
mRNA, we next tested whether KH-3 could block these HuR
functions by determining the mRNA half-life and the encoded
protein expression levels in MDA-MB-231 and SUM159 cells.
KH-3, but not its inactive analog KH-3B, decreased the half-life of
Bcl-2, Mis2 and XIAP mRNA (Fig. 3c–h). Similarly, the protein
expression levels of Bcl-2, Msi2 and XIAP were reduced by KH-3
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Fig. 2 Identification of KH-3 as an inhibitor of HuR–mRNA interaction. a HTS in ∼2000 compounds from the NCI libraries and in-house compounds
using FP assay. Shown here is the scattergram of compound activity expressed as % of inhibition. Median + 3 SD was used as a threshold to pick initial
hits. KH-3 and Aza-9 are two top hits. KH-3B has no activity in the screening. b Chemical structures of KH-3 and KH-3B. c Dose–response curve of KH-3
and negative control KH-3B disrupting HuR–AREMsi1 binding in FP assay using 10 nM HuR protein and 2 nM fluorescein-labeled Msi1 RNA (n= 3). d Dose–
response curve of KH-3 and KH-3B disrupting HuR–AREMsi1 binding in ALPHA assay using 100 nM HuR RRM1/2 protein and 25 nM biotin-labeled Msi1
RNA (n= 3). e SPR analysis of KH-3 binding to immobilized full-length HuR protein. Six doses were used and duplicated. f Computational docking of KH-3
and KH-3B to HuR RRM1/2. The protein is shown in surface representation with positive charges in blue and negative charges in red. KH-3 (green) and KH-
3B (magenta) are shown in sticks. g Cellular thermal shift curves of HuR in MDA-MB-231 cells treated with DMSO or 20 μM KH-3, values are mean from
two independent experiments. h Representative western blot results from one experiment. i, j Pull-down analysis of KH-3 disrupting AREMsi1 oligo binding
to endogenous HuR in MDA-MB-231 cells. Random oligo is used as a negative control of the assay and unlabeled AREMsi1 oligo is used as a positive
control. i Representative western blot result from one experiment. j Quantified relative HuR expression. Values are mean ± SD from n= 3 independent
experiments (**P < 0.01, one-way ANOVA). k RNP IP analysis of HuR bound mRNAs affected by KH-3 in MDA-MB-231 cells. Isotype IgG is used as a
negative control of HuR antibody. Values are mean ± SD from n= 3 independent experiments (***P < 0.001, two-way ANOVA).
Fig. 3 KH-3 inhibits breast cancer cell growth and destabilizes HuR targets. a, b MTT-based cytotoxicity of KH-3 against a panel of TNBC cell lines (a)
and MDA-MB-231 cells, sgControl and two HuR KO clones (b). c–h Half-life of Bcl-2, Msi2 and XIAP mRNA in MDA-MB-231 (c–e) and SUM159 (f–h) cells
treated with 5 μg/mL actinomycin D together with DMSO, KH-3 or KH-3B. Data are mean ± SD from n= 3 independent experiments (*P < 0.05, **P < 0.01,
***P < 0.001, two-way ANOVA).
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but not KH-3B as compared to DMSO (Fig. 4a–d and
Supplementary Fig. 3). KH-3B decreased about 25% of XIAP
protein level at 10 µM. Meanwhile, HuR protein levels were not
decreased by KH-3 treatment, which indicates that KH-3 works
through disruption of HuR–mRNA interactions without HuR
protein degradation.
KH-3 inhibits breast cancer cell migration and invasion. To
determine if KH-3 treatment yields similar effect on cell invasion
to HuR depletion, we carried out scratch and invasion assays in
MDA-MB-231 and SUM159 cells. In the scratch assay, the wound
width was significantly wider in samples treated with KH-3 for
24 h compared to DMSO treatment, which indicates that cell
migration is inhibited by KH-3 (Fig. 5a–c). In the invasion assay,
KH-3 decreased invaded cell numbers in a dose-dependent
manner while KH-3B had no effect (Fig. 5d–f).
We then explored the KH-3 mechanism of action in blocking
cell migration and invasion using a qPCR array that consists of 88
human tumor invasion/metastasis genes. A heatmap view with
hierarchical clustering revealed substantial similarities in the gene
expression profile (Nine undetectable genes were excluded) for
KH-3 treated cells to that for HuR KO1 clone (Fig. 5g). KH-3
treatment upregulated several metastatic suppressors (e.g., CD82
and CDH1)34 and downregulated several genes frequently over-
expressed in breast cancer lung metastasis (such as CDH2)35. The
induction of CDH1 expression was verified by CDH1 promoter/
luciferase reporter assay. Compared to DMSO control, KH-3
increased the relative luciferase signals in a dose-dependent
manner in cells transfected with a vector containing firefly
luciferase gene driven by CDH1 promoter, but not in cells
transfected with a control vector (Fig. 5h). As CDH1 encodes
protein E-cadherin, which is an epithelial marker, the induction
of CDH1 may suggest that KH-3 inhibits cell migration and
invasion through blockade of epithelial–mesenchymal transition.
KH-3 inhibits the interaction between HuR and FOXQ1
mRNA. Binding to the mRNA 3′-UTR and promoting the
expression of Snail, which leads to the repression of CDH1 and
subsequently its encoded protein E-cadherin, is one of the
mechanisms that HuR is reportedly involved in cell migration14.
However, in our study, Snail appears not to be a direct HuR target
in either MDA-MB-231 or SUM159 (Supplementary Fig. 7a).
Meanwhile, KH-3 treatment does not decrease, but increases,
Snail mRNA levels (Supplementary Fig. 7b). So far we do not
know how KH-3 upregulates CDH1 and whether this regulation
is dependent on HuR. To address these questions and to identify
direct HuR targets contributing to HuR’s function in breast
cancer invasion and metastasis, we employed two types of high-
throughput analysis: RIP-seq and RNA-seq. In RIP-seq, anti-HuR
antibody was used to immunoprecipitate endogenous HuR-RNA
complexes in MDA-MB-231 cells and the HuR-bound RNAs
were identified to obtain a list of direct HuR targets by comparing
to that of isotype IgG control (Supplementary Data 1). RNA-seq
was performed using mRNA samples collected from MDA-MB-
231 cells treated with KH-3 and the result disclosed a list of genes
affected by KH-3 treatment by comparing to that of DMSO
control (Supplementary Data 2). Gene set enrichment analysis
(GSEA) of epithelial-mesenchymal transition hallmark set for
RNA-seq data exhibited that EMT genes were enriched in DMSO
group compared to KH-3 group (Supplementary Fig. 7c), indi-
cating that KH-3 treatment inhibits EMT signature. Intersecting
the two lists from RIP-seq and RNA-seq revealed a set of 995
common targets (Fig. 6a). Among them, FOXQ1, a transcription
factor that belongs to Forkhead box protein family, is one of the
top genes inhibited by KH-3. FOXQ1 has been reported to be
Fig. 4 KH-3 decreases protein expression levels of HuR targets. a–d Protein levels of Bcl-2, Msi2, XIAP, and HuR in MDA-MB-231 (a, b) and SUM159 (c,
d) cells treated with DMSO, KH-3 or KH-3B at the indicated doses for 48 h. α-Tubulin is used as loading control. Representative western blot results from
one experiment in MDA-MB-231 (a) and SUM159 (c) cells. Quantified relative expression of HuR and downstream target Bcl-2, Msi2 and XIAP in MDA-
MB-231 (b) and SUM159 (d) cells. Values are mean ± SD from n= 3 independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA).
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Fig. 5 KH-3 inhibits breast cancer cell migration and invasion and promotes CDH1 expression. a–c Scratch assay in MDA-MB-231 and SUM159 cells
treated with DMSO or KH-3. a, b Representative images of cell migration at 0 and 24 h after scratching with indicated treatment in MDA-MB-231 (a) and
SUM159 (b) cells, scale bars: 50 μm. cWound widths in two cell lines 24 h after scratching and treatment (***P < 0.001, t-test, n= 3). d–f Invasion assay in
MDA-MB-231 and SUM159 cells treated by DMSO, KH-3B or KH-3. d, e Representative images of stained invaded cells with indicated treatment in MDA-
MB-231 (d) and SUM159 (e) cells, scale bars: 200 μm. f Invaded cell numbers per image in both cell lines with indicated treatment (***P < 0.001, one-way
ANOVA, n= 6). g The heatmap view of PCR pathway array focusing on invasion and metastasis related genes. The relative mRNA levels were presented
as z score, each treatment was triplicated. h CDH1 luciferase reporter assay in HEK 293FT cells treated by DMSO, KH-3B or KH-3. Values are mean ± SD
from n= 4 independent experiments (**P < 0.01, ***P < 0.001, two-way ANOVA).
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implicated in breast cancer EMT and metastasis, negative reg-
ulation of CDH1 expression is one of the mechanisms36. FOXQ1
protein level is upregulated in MDA-MB-231, its subclone 2LMP,
MDA-MB-453, MDA-MB-468 and SUM159 cells compared to
Human Mammary Epithelial Cells (HMEC). Reversely, the
expression of E-cadherin is lost in those cells with high FOXQ1
(Fig. 6b and Supplementary Fig. 3). This result suggests a negative
correlation between FOXQ1 and E-cadherin expression. There is
no obvious correlation between FOXQ1 and total HuR expression
among different breast cancer cell lines, since total HuR is
expressed in all breast cancer cell lines tested.
We validated FOXQ1 as a direct HuR target using RNA pull
down and RNP IP assays in MDA-MB-231 and SUM159 cells.
Meanwhile, we examined whether KH-3 could disrupt the
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HuR–FOXQ1 mRNA interaction. We designed a biotinylated 18-
mer AREFOXQ1 RNA oligomer from 3′-UTR of FOXQ1 mRNA
to pull down endogenous HuR. The biotinylated AREFOXQ1 RNA
oligomer, but not oligomer with random sequence, could
considerably pull down HuR protein, whereas the 10-fold excess
of unlabeled AREFOXQ1 RNA oligomer completely abolished the
HuR protein pulled down, indicating a strong HuR–AREFOXQ1
interaction (Fig. 6c, d). KH-3, but not KH-3B, decreased the
amount of HuR protein pulled down by biotinylated AREFOXQ1
RNA oligomer, demonstrating the disruption of HuR–AREFOXQ1
interaction by KH-3 (Fig. 6c, d). In the RNP IP assay, compared
to isotype IgG, the marked enrichment of FOXQ1 mRNA
immunoprecipitated by HuR antibody confirmed the binding of
HuR to FOXQ1 mRNA. KH-3, but not KH-3B, disrupted the
HuR–FOXQ1 mRNA interaction in a dose-dependent manner
(Fig. 6e, f).
We also investigated if KH-3 could destabilize FOXQ1 mRNA.
However, there were minor differences in mRNA half-lives
among different treatment groups (Supplementary Fig. 8a, b). It is
possibly because the half-life of FOXQ1 mRNA is very short (ca.
1 h, Supplementary Fig. 8a, b) and KH-3 is not quick enough to
act. Therefore, we checked FOXQ1 mRNA at different time
points after treatment. Compared with that of DMSO, KH-3
decreased FOXQ1 mRNA levels in a time-dependent manner
(Fig. 6g, h). However, the mRNA level was only reduced 20% at 8
h in MDA-MB-231 and about 40% at 4 h in SUM159, which
means it takes longer time for KH-3 to act than the half-life of
FOXQ1 mRNA. KH-3B caused about 20% reduction of FOXQ1
mRNA at 24 h in SUM159.
We also determined FOXQ1 mRNA levels in HuR KO clones
treated with KH-3 to explore whether the reduction of FOXQ1
mRNA level by KH-3 is dependent on HuR or not. As shown in
Supplementary Fig. 8c, although KH-3 treatment still decreased
FOXQ1 mRNA level in two HuR KO clones, the reduction was
significantly attenuated compared to that in sgControl cells,
indicating that the inhibitory effect of KH-3 on FOXQ1 was at
least partially dependent on HuR.
Given HuR mainly binds to the 3′-UTR of target mRNA, we
verified the inhibitory effect of KH-3 on FOXQ1 3′-UTR using 3′-
UTR reporter assay. KH-3, but not KH-3B, reduced the luciferase
signal in cells transfected with vector bearing FOXQ1 3′-UTR,
while it did not have significant effect on cells with control vector
in MDA-MB-231 and SUM159 cells (Fig. 6i, j), indicating a
specific inhibition of FOXQ1 3′-UTR.
FOXQ1 contributes to HuR’s role in promoting cell invasion.
We sought to determine if FOXQ1 contributes to HuR’s func-
tional role in promoting breast cancer cell invasion by induction
of exogenous FOXQ1. As shown in Fig. 7a, b, compared to
sgControl cells transfected with control vector, HuR KO clones
transfected with control vector had fewer invaded cells. However,
exogenous FOXQ1 partially rescued invasive capability impaired
by HuR knockout as the invaded cell number increased in HuR
KO clones transfected with FOXQ1 cDNA compared to those
transfected with control vector, although the invaded cell num-
bers were still fewer than sgControl cells. This result indicates that
FOXQ1 is one of the downstream targets that contribute to HuR’s
role in cell invasion. Overexpression of FOXQ1 was verified
(Fig. 7c). We also determined the mRNA levels of CDH1 and
CD82 (Fig. 7c), two genes upregulated by HuR KO and KH-3 in
qPCR array. HuR KO clones transfected with control vector had
significantly higher CDH1 mRNA levels compared to sgControl
cells transfected with control vector. Overexpression of FOXQ1
abolished the induction CDH1 expression in both HuR KO
clones, but HuR KO1 still had higher CDH1 than basal level of
sgControl while the level of CDH1 in HuR KO2 was not sig-
nificantly different to basal level. CD82 mRNA levels was sig-
nificantly increased in HuR KO2 clone compared to sgControl
cells. Exogenous FOXQ1 did not affect CD82 mRNA level in
sgControl cells and HuR KO clones. These data suggest that
FOXQ1 contribute to HuR’s role in cell invasion through
downregulating CDH1.
We then tested if FOXQ1 overexpression could also rescue cell
invasive capability inhibited by KH-3. As shown in Fig. 7d, e,
compared to DMSO, KH-3 significantly inhibited invaded cell
numbers in MDA-MB-231 cells transfected with control vector.
However, exogenous induction of FOXQ1 eliminated this effect as
KH-3 treatment did not decrease invaded cell numbers in cells
transfected with FOXQ1 cDNA, demonstrating that KH-3
inhibits cell invasion through suppression of FOXQ1 expression.
Similarly, we checked CDH1 and CD82 mRNA levels (Fig. 7f).
KH-3 markedly induced CDH1 expression in cells transfected
with control vector while this induction was recalled by
overexpression of FOXQ1. FOXQ1 overexpression had no effect
on KH-3 induced CD82 upregulation. We also detected the
protein expression levels of HuR targets (Fig. 7g, h and
Supplementary Fig. 3). KH-3 decreased FOXQ1 protein level,
which was abolished by FOXQ1 overexpression. KH-3 also
reduced protein levels of other HuR targets such as Bcl-2, Msi2
and β-catenin, none of which were significantly affected by
FOXQ1 overexpression.
KH-3 inhibits breast cancer growth and metastasis in vivo. The
anti-tumor efficacy of KH-3 was examined in MDA-MB-231
orthotopic xenograft model. Tumor-bearing female athymic mice
were randomized into two groups and treated with either vehicle
control or 100 mg/kg KH-3, via intraperitoneal injection three
times/week for three weeks. KH-3 significantly inhibited tumor
growth, resulting in 60% tumor regression after three-week
treatment (Fig. 8a). KH-3 reduced the protein expression levels of
HuR targets in tumor tissues as well as the induction of E-
cadherin expression (Fig. 8b and Supplementary Fig. 3).
The anti-metastatic potential of KH-3 was then explored in an
experimental metastasis model by injecting luciferase-expressing
2LMP cells into the lateral tail vein of athymic mice. The mice
were randomized into two groups and treated with either vehicle
or KH-3 via intraperitoneal injection five times/week for five
weeks. We monitored the tumor initiation and progression in
Fig. 6 FOXQ1 is a HuR target and KH-3 disrupts HuR–FOXQ1 interaction. a Venn diagram depicting the number of targets identified in two independent
RNA-seq experiments. FOXQ1 is a direct HuR target, which is also one of the top mRNAs decreased by KH-3 treatment. b Protein expression levels of HuR,
FOXQ1 and E-cadherin in HMEC and a panel of TNBC cell lines. c, d Pull-down analysis of KH-3 disrupting AREFOXQ1 oligo binding to endogenous HuR in
MDA-MB-231 and SUM159 cells. c Representative western blot result from one experiment. d Quantified relative HuR expression. Values are mean ± SD
from n= 3 independent experiments (*P < 0.05, ***P < 0.001, one-way ANOVA). e, f RNP IP analysis of HuR bound FOXQ1 mRNA affected by KH-3 in
MDA-MB-231 (e) and SUM159 (f) cells. Values are mean ± SD from three independent experiments (**P < 0.01, ***P < 0.001, one-way ANOVA). g, h
Relative FOXQ1 mRNA levels in MDA-MB-231 (g) and SUM159 (h) cells treated with DMSO, KH-3 or KH-3B at the indicated time points. Values are mean
± SD from n= 3 independent experiments (***P < 0.001, two-way ANOVA). i, j FOXQ1 3′-UTR luciferase reporter assay in MDA-MB-231 (i) and SUM159
(j) cells treated by DMSO, KH-3B or KH-3. Values are mean ± SD from n= 3 independent experiments (***P < 0.001, two-way ANOVA).
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lung by bioluminescent imaging as well as the survival.
Supplementary Fig. 9a presented representative images for the
same mice at three stages: (I) mouse 3 with initial detection of
pulmonary metastasis; (II) mouse 1 with initial detection of
pulmonary metastasis and mouse 3 with pulmonary metastasis
progression; (III) mouse 1 with pulmonary metastasis progression
and near moribund mouse 3 with extensive pulmonary
metastases. KH-3 treatment significantly delayed the initiation
of pulmonary metastases (Fig. 8c). The median time for the two
groups was 38 and 71 days, respectively. KH-3 also decreased the
Fig. 7 FOXQ1 contributes to HuR role in promoting cell invasion. a, b Invasion assay in parental MDA-MB-231 cells, sgControl and two HuR KO clones
transfected with control vector or vector containing FOXQ1 cDNA. a Representative images of stained invaded cells, scale bars: 200 μm. b The number of
invaded cells per image (***P < 0.001, one-way ANOVA, n= 6). c mRNA expression levels of FOXQ1, CDH1 and CD82 in parental MDA-MB-231 cells,
sgControl and two HuR KO clones transfected with control vector or vector containing FOXQ1 cDNA. Values are mean ± SD from n= 3 independent
experiments (*P < 0.05, ***P < 0.001, two-way ANOVA). d, e Invasion assay in MDA-MB-231 cells transfected with control vector or vector containing
FOXQ1 cDNA together with DMSO or 10 μM KH-3 treatment. d Representative images of stained invaded cells, scale bars: 200 μm. e The number of
invaded cells per image (***P < 0.001, one-way ANOVA, n= 6). f mRNA expression levels of FOXQ1, CDH1 and CD82 in MDA-MB-231 cells transfected
with control vector or vector containing FOXQ1 cDNA together with treatment of DMSO or 10 μM KH-3. Values are mean ± SD from n= 3 independent
experiments (**P < 0.01, ***P < 0.001, two-way ANOVA). g, h Protein expression levels of FOXQ1, Bcl-2, Msi2, β-catenin, and HuR in MDA-MB-231 cells
transfected with control vector or vector containing FOXQ1 cDNA together with treatment of DMSO or KH-3 at the indicated doses for 48 h. α-Tubulin is
used as loading control. g Representative western blot results from one experiment. h Quantified relative expression of HuR and downstream targets.
Values are mean ± SD from n= 3 independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA).
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metastasis incidence. All mice (9/9) in control group had
pulmonary metastases while 77.7% (7/9) mice in KH-3 group
had pulmonary metastases at the end of experiment. KH-3
treatment significantly improved the survival time of mice as well.
The median survival time in control group was 62 days while
81 days in KH-3 group (Fig. 8d). At the conclusion of the
experiment, all lung tissues were collected and performed
immunohistochemistry staining. Supplementary Fig. 9b presented
representative IHC H&E staining images of lungs, which
displayed tumor cells surrounded by lung cells. Besides the
primary outcome, we also monitored side effects of KH-3. KH-3
treatment caused minor diarrhea in some mice. Some mice had
swollen abdomens starting the fourth week of treatment, which
may be induced peritonitis due to repeated intraperitoneal
injection. No other side effects were noticed. The mice in KH-3
group gained weight similar to those in control group during the
first 43 days of the experiment (Supplementary Fig. 9c). After
that, the mice in control group started to die so the weight curve
could not be plotted. These data suggest that KH-3 is a potent and
safe agent to inhibit breast cancer metastasis in vivo.
We also investigated the anti-metastatic potential of KH-3 in a
4T1 experimental metastatic model by injecting luciferase-
expressing 4T1 cells into the lateral tail vein of BALB/c mice.
The treatment dose and schedule were the same as used in 2LMP
model. We used bioluminescence imaging to monitor the tumor
initiation and progression. However, the imaging results of some
mice were not consistent with the necropsy results obtained at the
end of experiment (many lung tumor nodules were not
luminescent). Therefore, the effect of KH-3 on tumor initiation
was unable to be determined. Nevertheless, overall survival of
mice was evaluated. Supplementary Fig. 9d presented the survival
curves of mice in two groups. KH-3 treatment improved the
Fig. 8 KH-3 inhibits breast cancer growth and metastasis in vivo. a In vivo anti-tumor efficacy of KH-3 in MDA-MB-231 orthotopic xenograft model. KH-3
treatment significantly inhibits the tumor growth compared to the vehicle control (n= 12, **P < 0.01, ***P < 0.001, two-way ANOVA). b Protein expression
levels of HuR and downstream targets in tumor tissues after treatment. α-Tubulin is used as loading control. c, d Kaplan–Meier analysis of the initiation of
pulmonary metastases (c) and overall survival of mice (d) comparing treatment with vehicle control or KH-3 in an experimental metastasis model (n= 9,
*P < 0.05, **P < 0.01, log-rank test). e Schematic of screening for HuR inhibitors that bind to HuR and block HuR function. f Proposed working model of KH-
3 inhibiting breast cancer invasion and metastasis.
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survival time of mice. The median survival time in control group
was 36.5 days and in KH-3 group was 52.5 days.
Discussion
In the current study, we find that high cytoplasmic HuR
expression correlates with advanced tumor grade of breast cancer
and poor overall and distant disease-free survival of breast cancer
patients. Knocking out HuR in breast cancer cell lines not only
decreases cells growth but also impairs cell invasion capability.
These findings demonstrate that HuR is a promising therapeutic
target for inhibiting breast cancer invasion and metastasis as well
as tumor progression.
During the last decade, we and others reported the identifica-
tion of small molecules that interfere HuR–RNA interactions
through high-throughput screening23 and one group published
the structure-based design and optimization of an initial top hit22.
Here, we identify a inhibitor KH-3 that disrupts HuR–mRNA
interactions through competitively binding to HuR and therefore
blocks HuR functions, leading to the decay of HuR target mRNA
and/ or reduction of translation (Fig. 8e, f). As a result, KH-3
inhibits breast cancer cell growth and invasion in vitro and
prohibits tumor growth and experimental lung metastasis in vivo.
HuR was reported to bind to 3′-UTR of Snail mRNA and
promote its expression, which is one of the mechanisms that HuR
is implicated in cell migration14. However, Snail is not a direct
HuR target in the two breast cancer cell lines we tested. By
intersecting the results from RIP-seq and RNA-seq and the
follow-up validation, we find another transcriptional factor,
FOXQ1, as a direct target of HuR in MDA-MB-231 and SUM159
cells, and that KH-3 can disrupt the interaction between HuR and
FOXQ1 mRNA. Recently, a number of studies revealed the
implication of FOXQ1 in cancer progression and metastasis36–38.
Similar to Snail, FOXQ1 negatively regulates CDH1, by directly
binding to the promoter region of CDH136. In our study, FOXQ1
overexpression partially rescues upregulated CDH1 expression
induced by HuR CRISPR KO and cell invasive capability pro-
hibited by HuR CRISPR KO. Therefore, FOXQ1 is one of the
HuR direct mRNA targets that contributes to HuR’s role in breast
cancer invasion and metastasis, potentially through promoting
epithelial-to-mesenchymal transition. FOXQ1 was also reported
to positively regulate several other genes involved in cancer
invasion and metastasis, such as Snail39 and LAMA437. LAMA4,
which encodes a secreted ECM protein, is found to promote
tumor re-initiation in multiple organ microenvironments37. KH-
3 treatment also reduces LAMA4 expression (Supplementary
Fig. 10). Hence, FOXQ1 may also contribute to HuR’s role in
breast cancer invasion and metastasis via increasing the expres-
sion of protein that degrades ECM. However, more experiments
are needed to support this hypothesis.
In qPCR array analyses, besides promoting the expression of
CDH1, KH-3 treatment also induces the expression of CD82, a
tumor metastasis suppressor. It is reported that transcription of
CD82 can be downregulated by β-catenin (CTNNB1)40. β-catenin
was found as a direct HuR target in MDA-MB-23141, also verified
in our study (β-catenin is one of the 995 overlaid genes of RIP-seq
and RNA-seq, Fig. 6a). As FOXQ1 overexpression has no effect
on KH-3 induced upregulation of CD82 and inhibition of β-
catenin (Fig. 7f–h), we propose a working model that KH-3
disrupts HuR–FOXQ1 and HuR-β-catenin signaling axes in
parallel, leading to the inhibition of invasion and metastasis
(Fig. 8e, f). However, the role of HuR-β-catenin axis in breast
cancer invasion and metastasis needs to be confirmed, and
whether HuR inhibition induced CD82 upregulation is related to
β-catenin reduction, remains further studies. HuR may also
implicate in breast cancer invasion and metastasis through other
HuR–mRNA axes not tested in current study and these axes may
or may not be interfered by KH-3.
As a small molecule inhibitor of HuR, KH-3 phenocopies HuR
knockout in most of assays but less efficiently. KH-3 treatment
results in ~60% tumor growth regression in xenograft model
while HuR KO reduce tumor growth more than 95%. The anti-
tumor efficacy of MS-444 and DHTS, two reported HuR inhibi-
tors, were evaluated in colorectal cancer xenograft models.
Treatment of HCT116 xenografts with 25 mg/kg MS-444, which
blocks HuR function by interfering HuR cytoplasmic localization,
results in about 1.7-fold reduction in tumor size26. Treatment of
HCT116 xenografts with 10 mg/kg DHTS, which blocks HuR
function by interfering the binding of HuR to RNA, results in ~4-
fold reduction in tumor size27. The in vivo efficacy of three HuR
inhibitors strongly supports that targeting HuR is a promising
therapeutic strategy. However, like most molecularly targeted
therapeutics, KH-3 may need to be combined with conventional
chemotherapy regimens to maximize efficacy for inhibiting tumor
progression and metastasis.
It was reported that DNA damaging agents could induce
cytoplasmic translocation of HuR in pancreatic cancer cells42.
Our preliminary studies show that docetaxel, a first-line che-
motherapy of TNBC, also leads to cytoplasmic HuR accumulation
and subsequently upregulation of HuR downstream targets.
Likewise, HuR also promotes the translation of several target
mRNA that encode proteins involved in cancer treatment
resistance29,43,44. Hence, combinations of HuR inhibitor with
chemotherapy have high chance to display synergistic effect and
overcome the acquired chemoresistance, which will be further
explored in our development of HuR inhibitors.
In conclusion, the small molecule inhibitor identified here can
be used as a potent chemical probe to delineate HuR’s functional
roles and as a lead compound to develop novel molecular ther-
apeutics targeting HuR. This study provides the therapeutic
potential of HuR inhibition for lethal metastatic breast cancer
with HuR overexpression.
Methods
Cell culture and reagents. Human TNBC cell line BT-549, Hs 578T, MDA-MB-
231, MDA-MB-453, and MDA-MB-468 as well as mouse TNBC cell line 4T1 were
purchased from American Type Culture Collection (ATCC) and the 2LMP sub-
clone which was generated from MDA-MB-231 formed lung metastasis in mice
was a kind gift from Dr. Marc Lippman. Human embryonic kidney (HEK) 293FT
cell line was purchased from ThermoFisher Scientific. These cell lines were cultured
in DMEM (Mediatech) supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich), 1% antibiotics (Mediatech). Human TNBC cell line SUM-149 and SUM-
159 were obtained from Asterand45 and maintained in Ham’s F12 (Mediatech)
with 5% FBS, 10 μg/mL insulin and 500 ng/mL hydrocortisone (all from Sigma-
Aldrich). Human Mammary Epithelial Cells (HMECs) were purchased from
ATCC and cultured in Mammary Epithelial Cell complete medium (basal medium
plus growth kit). All cell lines were either recently obtained or monitored by STR
profiling.
(E)-3-(5-((4-(tert-Butyl)phenyl)sulfonamido)benzo[b]thiophen-2-yl)-N-
hydroxyacrylamide (KH-3) was synthesized from (E)-3-(5-((4-(tert-butyl)phenyl)
sulfonamido)benzo[b]thiophen-2-yl)acrylate (KH-3B) followed a literature46. To a
solution of ethyl (E)-3-(5-((4-(tert-butyl)phenyl)sulfonamido)benzo[b]thiophen-2-
yl)acrylate47 (KH-3B, 4.0 g, 9.02 mmol) in methanol (20 mL) was added dropwise
DBU (4.1 mL, 27.1 mmol). After 10 min, 50% aq hydroxylamine (5.5 mL) was
added dropwise and the reaction mixture was allowed to stir at RT for 1 h. The
reaction mixture was concentrated and the crude residue purified via silica gel
MPLC (100% DCM to 10% MeOH in DCM) to afford an impure product, which
was further purified by reverse phase HPLC (10% methanol in water to 100%
methanol) to give the title compound as a light yellow solid (KH-3, 3.70 g, 95%
yield). 1H NMR (400MHz, DMSO-d6): 7.79 (d, J= 8.8 Hz, 1 H), 7.71–7.54
(complex, 7 H), 7.16 (m, 1 H), 6.24 (d, J= 15.4 Hz, 1 H), 1.23 (s, 9 H); 13C NMR
(100MHz, DMSO-d6): 161.9, 155.9, 141.2, 140.2, 136.9, 135.6, 134.3, 131.8, 127.8,
126.6, 126.2, 123.4, 120.8, 119.5, 114.5, 48.7, 30.8; purity (UPLC, 254 nm): >96%.
KH-3 and KH-3B powder were dissolved in DMSO at 20 mM as stock solutions for
in vitro assays. KH-3 powder was dissolved in PBS with 5% ethanol and 5% Tween-
80 for animal studies.
The pCMV-XL5 vector with and without human FOXQ1 cDNA were obtained
from OriGene. The pEZX-MT06 reporter vector with and without human FOXQ1
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3′-UTR were obtained from GeneCopoeia. Antibodies against Bcl-2 (Cat# 2872,
1:500 dilution) and E-cadherin (Cat# 3195, 1:1000 dilution) were purchased from
Cell Signaling Technology, HuR (3A2, Cat# sc-5261, 1:500 dilution), FOXQ1 (H-
11, Cat# sc-166264, 1:500 dilution) and β-catenin (E-5, Cat# sc-7963, 1:500
dilution) were purchased from Santa Cruz Biotechnology. Anti-Msi2 (Cat#
Ab76148, 1:2000 dilution) antibody was obtained from Abcam, Anti-XIAP (Cat#
610717, 1:500 dilution) antibody was obtained from BD Biosciences and anti-α-
Tubulin (Cat# T5168, 1:4000 dilution) was obtained from Sigma-Aldrich. Anti-
mouse (Cat# 926-68070 and Cat# 926-32210) and anti-rabbit (Cat# 926-68071 and
Cat# 926-32211) IRDye secondary antibodies (1:15000 dilution) were purchased
from LI-COR Biosciences.
The cell growth, MTT-based cytotoxicity assay, colony formation, western blot
and qPCR (primers listed in Supplementary Table 2) were performed according to
our previous publications48,49. The protein expression and purification, AlphaLISA
assay, SPR, computational docking and mRNA stability assay were carried out as
we previously described17,18. The intensities of immunoblots were quantified using
Image Studio Ver 4.0 (LI-COR Biosciences) and normalized to loading control α-
Tubulin.
Patients and tissue microarray. The study cohort consisted of 140 patients
diagnosed with breast cancer who underwent primary surgical intervention
between January 2005 and September 2012. Among them, 139 patients’ survival
information with up to 132 months’ postoperative follow-up was documented.
Patients’ clinicopathologic variables, such as age, tumor grade and type, TNM
stage, AJCC stage, survival time, recurrence time and metastasis were obtained
from the medical records (Supplementary Table 1). The informed consent was
obtained from these 140 patients. This study was reviewed and approved by the
Institutional Review Board of the Air Force Medical University (Xi’an, China). A
tissue microarray (TMA) constructed from formalin-fixed, paraffin-embedded
tissue blocks from the above 140 patients was purchased from Shanghai Outdo
Biotech Company (Shanghai, China). All procedures of construction TMA were
performed as previously described50.
Immunohistochemistry staining. TMA staining was performed using standard
immunohistochemical staining procedures as previously described50. The HuR
antibody (Santa Cruz) was used in a dilution of 1:200. To confirm the specificity of
the primary antibody, tissue sections were incubated with control mouse IgG in the
absence of primary antibody. The percentage and the intensity of positively stained
cells were scored by inForm software and then verified by two pathologists inde-
pendently in a blinded manner. The percentage of positive stained cells was scored
as follows: 0, 1-25%, 26-75% and > 75%. The intensity of positive immunostaining
was classified into four categories: 0, 1, 2, and 3 representing no visible staining;
light brown, mid-brown and dark brown staining, respectively, with the same
intensity covering more than 75% of the staining area. The intensity of cytoplasmic
HuR staining is either 0 or 1. For the statistical analysis, the stained tumor tissues
were divided into two groups: the low-expression group and the high-expression
group. The low-expression group included tissues with negative staining or light
staining with 1 + staining in ≤75% of cells; the high-expression group included
tissues with intense staining with 1 + staining in > 75% of cells. Five specimens
either damaged or not well stained were excluded, which left us 135 specimens for
the analysis.
Establishment of stable cell lines. The GIPZ lentiviral short hairpin RNA
(shRNA) constructs targeting human HuR (NM_001419.2) as well as GIPZ and
TRIPZ empty vectors were purchased from Dharmacon. Same shRNA from GIPZ
system were cloned into TRIPZ empty vector. The lentiCRISPRV2 vector was
purchased from AddGene and the control single guide RNA (sgRNA) and HuR
sgRNA were cloned into the vector as described51,52. The HuR lentiviral shRNA,
sgRNA or control shRNA and sgRNA were co-transfected into HEK 293FT cells
with the packaging plasmids pMD2.G and psPAX2 (both from AddGene). MDA-
MB-231 and SUM159 cells were infected with virus medium and then selected with
1.5 µg/mL puromycin. Expression of inducible shRNA was induced by 0.5 µg/mL
doxycycline. Single clones were generated by limiting dilution. Knock-down or
knock-out of HuR expression was verified by qPCR and western blot.
Invasion assay. To analyze cell invasion, Corning BioCoat Matrigel Invasion
Chambers (Bedford, MA) were used. (1–1.5) ×105 cells in 0.5 mL of serum free
medium were seeded in Matrigel-coated upper chambers and incubated for 22 h.
Cells were fixed with 95% methanol and stained with 0.1% crystal violet. Non-
invaded cells were removed from the upper surface of the membrane by cotton
swabs. Cells that invaded were visualized and photographed with EVOS FL cell
imaging systems (Life Technologies, Bothell, WA) under ×4 and ×20
magnification.
Immunofluorescence. Cells were seeded on 4-well Lab-TekII chamber slide
(Fisher Scientific). Following fixation, permeabilization and blocking, cells were
incubated with HuR antibody (Santa Cruz, 1:100 dilution) or mouse IgG followed
with anti-mouse IgG-FITC antibody (Sigma). Nucleus were then stained with
DAPI. Images were taken with EVOS FL cell imaging systems (Life Technologies,
Bothell, WA) under ×4 and ×20 magnification.
Cellular thermal shift assay (CETSA). CETSA were carried out as reported
previously53. MDA-MB-231 cells were pre-treated with 20 µM KH-3 or DMSO for
1 h. Cells were then harvested and resuspended in PBS supplemented with com-
plete protease inhibitor cocktail. The cell suspensions were aliquoted into PCR
tubes and heated for 3 min at designated temperatures ranging from 42 to 54 °C
followed by cooling at 25 °C for 3 min. Subsequently, cell suspensions were freeze-
thawed three times using liquid nitrogen. The soluble fractions were then analyzed
by western blot. The band intensities were measured using Image Studio Ver 4.0
(LI-COR Biosciences) and normalized to α-Tubulin.
Fluorescence polarization assay. The FP assay for HTS and dose–response curve
was employed as previously described17. The only differences were that HTS was
performed in 96-well black plates with a final volume of 100 μL and the com-
pounds were screened at 20 μM concentration.
RNA pull-down and RNP IP. Two assays were carried out as previously described
with minor modifications17. For RNA pull-down, cell lysate was incubated with 16-
nt biotinylated Msi1 RNA oligo (1 μM), 18-nt biotinylated FOXQ1 oligo (5′-AU
UAUUUAUAUAUUUUUG-3′, 1 μM) or random RNA oligo (1 μM) for 30 min
with respective 10 μM unlabeled oligo, or DMSO, KH-3, KH-3B. For RNP IP, cells
pre-treated with DMSO, KH-3B or KH-3 for 6 h were lysed and incubated with
HuR antibody or mouse IgG (Sigma-Aldrich).
Luciferase reporter assay. For CDH1 reporter assay, HEK 293FT cells co-
transfected with pGL3 vector with or without CDH1 promoter (Addgene, #61798)
and renilla were treated with DMSO, KH-3 or KH-3B for 48 h. For FOXQ1 3′-UTR
study, MDA-MB-231 and SUM159 cells transfected with pEZX-MT06 reporter
vector with or without human FOXQ1 3′-UTR were treated with DMSO, KH-3 or
KH-3B at indicated doses for 24 h. The cells were then harvested and assayed using
the Dual-Glo Luciferase Assay (Promega). All firefly luciferase values were nor-
malized to the renilla luciferase values. Relative luciferase activity was calculated for
each treated sample by dividing normalized luciferase activity by that of DMSO
control.
Tumor invasion/metastasis qPCR array. Total RNA isolated from MDA-MB-
231 sgControl, HuR KO1, HuR KO2 and MDA-MB-231 cells treated with 10 μM
KH-3 or DMSO were reverse transcribed into complementary DNA, and amplified
by Human Tumor Invasion/Metastasis Primer Library (HTIM-I) from Real Time
Primers LLC (Elkins Park), which contains 88 primer sets directed against inva-
sion/metastasis related genes and 8 housekeeping gene primer sets as we described
previously54. The heatmap was generated by Heatmapper (http://www.heatmapper.
ca/) using Average Linkage as clustering method and Pearson as distance mea-
surement method.
RIP-seq and RNA-seq. RNA immunoprecipitated by HuR antibody or mouse IgG
control from MDA-MB-231 cells and total RNA from MDA-MB-231 cells treated
with DMSO or KH-3 were collected for library preparation. Each condition had
two biological replicate. The libraries were sequenced using Illumina Hiseq
2500 system at Genome Sequencing Core at the University of Kansas. The RIP-seq
dataset was mapped to the reference human genome hg38 using STAR. The cor-
responding peaks were then detected using HOMER55 and annotated using
ANNOVAR56. Finally, the RIP peaks that correspond to significant transcript
abundance change were identified and compiled. The RNA-Seq dataset contains
three groups: DMSO, 5 µM KH-3 and 10 µM KH-3. The DMSO group was con-
sidered as the control group. The reads were mapped against the transcript data-
bases annotated in GENCODE v2457 using STAR58 default parameters. The read
counts for each transcript were calculated using eXpress59. The differentially
expressed transcripts were detected using DESeq260 with a q-value cutoff of 0.05.
Animal study. Female athymic NCr-nu/nu mice and BALB/c mice of 4–6 weeks
old purchased from Charles River Laboratories were used for tumor formation and
efficacy studies. 0.5 × 106 MDA-MB-231 cells or 1 × 106 SUM159 cells in 0.2 mL
DMEM were inoculated to #2 mammary fat pad (MFP) of athymic nude mice.
Tumor sizes were measured using a caliper twice a week. Tumor volume was
calculated using the formula: (length × width2)/2, as we described previously49.
Tumor growth inhibition (T/C %) is defined as the ratio of the mean tumor volume
for the treated versus control group. For efficacy study in MFD model, mice were
randomized into two groups when tumors reached ~50 mm3 and treated with 100
mg/kg KH-3 or vehicle control. The treatment was administrated via intraper-
itoneal injection three times per week for three weeks. For 2LMP experimental
metastasis model, 0.5 × 106 2LMP cells stably expressing luciferase in 0.3 mL
DMEM were intravenously injected into tail veins of athymic nude mice. For 4T1
experimental metastasis model, 1 × 104 4T1 cells stably expressing luciferase in 0.1
mL DMEM were intravenously injected into tail veins of BALB/c mice. Immedi-
ately following injection, mice were imaged by bioluminescence to assure wide
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distribution and quality of the initial injection. The mice were then randomized
into two groups and treated with 50 mg/kg KH-3 or vehicle control via intraper-
itoneal injection five times per week for five (2LMP model) or four (4T1 model)
weeks. Bioluminescence imaging was taken weekly to monitor the metastasis
burden at lung using our Carestream In-Vivo MS FS PRO Imaging System. When
an image showed luminescent signaling at lung compared to background with
automatic setting, the mouse was considered with tumor initiation. Imaging was
taken twice a week thereafter first detectable signaling at lung. All animal experi-
ments were carried out according to the protocol approved by the Institutional
Animal Use and Care Committee at the University of Kansas.
Statistics and reproducibility. The GraphPad Prism 5.0 software was used for
statistical analysis. The association between cytoplasmic HuR staining and clin-
icopathologic factors was assessed by using Fisher’s exact test. The Kaplan–Meier
method and the log-rank test were used to compare overall survival, defined as the
time of patients from surgery until death, and distant disease-free survival, defined
as the time of patients from surgery until having metastasis (patients alive were
censored at the time of their last follow-up). Error bars in boxplots represent
minimum and maximum values. Error bars in bar charts represent standard
deviation (SD) except tumor growth data were expressed as mean ± standard error
of mean (SEM). Student’s t test, one-way analysis of variance (ANOVA) followed
by Tukey’s post hoc test and two-way ANOVA followed by Bonferroni multiple
comparison tests were employed to analyze the in vitro and in vivo data. The
Kaplan–Meier method and the log-rank test were also used to analyze tumor
initiation and overall mouse survival. A threshold P < 0.05 was defined as statistical
significance. All in vitro experiments were repeated at least three time. Exact
sample sizes and number of replicates were indicated in the figure legends.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Both the RIP-seq and RNA-seq data are deposited at Gene Expression Omnibus under
accession number GSE129530. The source data underlying the graphs and charts
presented in the main figures are shown as Supplementary Data 3. All other data
supporting the findings of this study are available within the paper and Supplementary
Information.
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